Anti-Seizure Drugs Linked to a Quarter of Stevens-Johnson Syndrome Cases

Researchers from Canada have analyzed epidemiological data linking antiepilepsy drugs to Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN), rare but serious drug-induced skin conditions. The study, published in JAMA Dermatology in late August 2026, identifies antiseizure medications as a leading pharmaceutical cause of these reactions, accounting for roughly one-quarter of all drug-related SJS cases. The research indicates that pediatric patients face higher risk of severe cutaneous adverse reactions compared to adults treated with these medications.

Stevens-Johnson Syndrome typically begins with flu-like symptoms followed by painful rashes. When more than 30% of skin surface is affected, the diagnosis escalates to toxic epidermal necrolysis. Both conditions can cause permanent vision loss, skin scarring, sepsis, organ failure, respiratory failure, and death. Treatment requires immediate discontinuation of the suspected causative medication. The identified antiseizure drugs include commonly prescribed seizure-control agents used in epilepsy and other neurological disorders.

This is a curated brief from the PlaintiffWire news desk. Read the original report at AboutLawsuits.